Status:
COMPLETED
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
Lead Sponsor:
Hanyang University
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3 Studies rarely address the...
Detailed Description
The working hypothesis is that Adding vitamin D to conventional Peg/RBV therapy for naïve, genotype 1-3 patients with chronic HCV infection significantly improves RVR, EVR additionally.
Eligibility Criteria
Inclusion
- Chronic genotype 1-3 HCV infection
- Treatment Naive
Exclusion
- Child B and C
- HCC patients
- Pregnancy
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2018
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT01439776
Start Date
September 1 2011
End Date
January 20 2018
Last Update
March 6 2023
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Soonchunhyang university Hospital Cheonan
Cheonan, Chungcheongnam-do, South Korea, 330721
2
Soonchunhyang university hospital Bucheon
Bucheon-si, Gyeonggi-do, South Korea, 420767
3
HANYANG University Guri Hospital
Guri-si, Gyeonggido, South Korea, 471701
4
Bundang Jesaeng Hospital
Seongnam, Gyeonggido, South Korea, 463774